Castle biosciences presents new data demonstrating decisiondx®-scc complements current risk assessment methods in patients with cutaneous squamous cell carcinoma of the head and neck

Friendswood, texas--(business wire)---- $cstl #ahns--castle biosciences announced a podium presentation at the american head & neck society (ahns) 10th international conference on head and neck cancer.
CSTL Ratings Summary
CSTL Quant Ranking